EMEA-001441-PIP01-13-M02

Key facts

Invented name
Ozempic
Active substance
semaglutide
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0036/2019
PIP number
EMEA-001441-PIP01-13-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of type 2 diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novo Nordisk A/S
Denmark
Tel. +45 3079 0235
E-mail: paediatrics@novonordisk.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating